Skip to main content

Advertisement

SpringerLink
Log in

PSMA-based alpha therapy in prostate cancer

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data Availability

The statement is a summation of the references provided above on the treatment outcomes with PSMA-based alpha therapy

References

  1. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.

    Article  CAS  PubMed  Google Scholar 

  2. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ, VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397–406.

    Article  CAS  PubMed  Google Scholar 

  4. Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4.

    Article  CAS  PubMed  Google Scholar 

  5. Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted alpha therapy of mCRPC with 225Actinium-PSMA-617: swimmer-plot analysis suggest efficacy regarding duration of tumor-control. J Nucl Med. 2018;59:795–802.

    Article  CAS  PubMed  Google Scholar 

  6. Rosar F, Hau F, Bartholomä M, Maus S, Stemler T, Linxweiler J, Ezziddin S, Khreish F. Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy. Theranostics. 2021;11:4050–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ballal S, Yadav MP, Sahoo RK, Tripathi M, Dwivedi SN, Bal C. 225 Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate. 2021;8:580–91.

    Article  Google Scholar 

  8. Lee DY, Kim YI. Effects of 225Ac-Labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: a meta-analysis. J Nucl Med. 2022;63:840–6.

    Article  CAS  PubMed  Google Scholar 

  9. Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, Davis C, Mahapane J, Corbett C, Vorster M, Morgenstern A. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129–38.

    Article  CAS  PubMed  Google Scholar 

  10. Lawal IO, Morgenstern A, Vorster M, Knoesen O, Mahapane J, Hlongwa KN, Maserumule LC, Ndlovu H, Reed JD, Popoola GO, Mokoala KMG, Mdlophane A, Bruchertseifer F, Sathekge MM. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:3581–92.

    Article  CAS  PubMed  Google Scholar 

  11. Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Mdlophane A, Maes A, Mokoala K, Mathabe K, Van C, Wiele D, Morgenstern A. mCRPC patients receiving 225Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting: response to treatment and survival analysis. J Nucl Med. 2022;63:1496–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Mokoala K, Reed J, Maseremule L, Ndlovu H, Hlongwa K, Maes A, Morgenstern A, Van de Wiele C. 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings. Eur J Nucl Med Mol Imaging. 2023;50:2210–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Feuerecker B, Kratochwil C, Ahmadzadehfar H, Morgenstern A, Eiber M, Herrmann K, Pomykala KL. Clinical translation of targeted α-therapy: an evolution or a revolution? J Nucl Med. 2023;64:685–92.

    Article  CAS  PubMed  Google Scholar 

  14. Sathekge MM, Bruchertseifer F, Vorster M, Morgenstern A, Lawal IO. Global experience with PSMA-based alpha therapy in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;49:30–46.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Research Infrastructure (NuMeRI), University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa

    Mike Sathekge

  2. Joint Research Centre, European Commission, Karlsruhe, Germany

    Alfred Morgenstern

Authors
  1. Mike Sathekge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfred Morgenstern
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mike Sathekge.

Ethics declarations

Ethics approval and consent to participate

Institutional Review Board approval was not required because the paper is an editorial.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sathekge, M., Morgenstern, A. PSMA-based alpha therapy in prostate cancer. Eur J Nucl Med Mol Imaging 50, 3506–3508 (2023). https://doi.org/10.1007/s00259-023-06384-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-023-06384-0

Search

Navigation